Mr. J. Cameron MacDonald reports

WESTAIM ANNOUNCES PARTICIPATION IN SECONDARY OFFERING OF SKYWARD SPECIALTY'S COMMON STOCK

The Westaim Corp. is selling 3.85 million shares of common stock of Skyward Specialty Insurance Group, Inc. (Nasdaq: SKWD), in an underwritten secondary public offering. In addition to Westaim, certain other stockholders of Skyward Specialty have also granted the underwriters a 30-day option to purchase up to an additional 577,500 shares. In the event the option is fully exercised, Westaim would sell an additional 137,500 shares.

Skyward Specialty will not receive any of the proceeds from the sale of the shares offered by the selling stockholders. The selling stockholders will bear the underwriting discounts and commissions associated with the sale of such shares and receive all the net proceeds.

Barclays Capital Inc. and Keefe, Bruyette & Woods, Inc., a Stifel company, are acting as joint lead book-running managers for the offering. JMP Securities, a Citizens Company, Piper Sandler & Co., Truist Securities, Inc., Raymond James & Associates, Inc., and BMO Capital Markets Corp. are acting as joint book-running managers for the offering. Siebert Williams Shank & Co., LLC is acting as co-manager for the offering.

About Westaim Corp.

Westaim is a Canadian investment company specializing in providing long-term capital to businesses operating primarily within the global financial services industry. The company invests, directly and indirectly, through acquisitions, joint ventures and other arrangements, with the objective of providing its shareholders with capital appreciation and real wealth preservation. Westaim's strategy is to pursue investment opportunities with a focus toward the financial services industry and grow shareholder value over the long term. Westaim's investments include significant interests in Skyward Specialty, Arena Investors and Arena Fincos. Skyward Specialty, the HIIG Partnership, Arena Fincos and Arena Investors are defined in the notes to Westaim's unaudited interim consolidated financial statements for the three months ended March 31, 2023, and 2022 and the management's discussion and analysis.